Millendo Therapeutics is a late-stage biopharmaceutical company focused on developing treatments for orphan endocrine diseases. Co.'s product candidate, livoletide (AZP-531), is a treatment for Prader-Willi syndrome, a genetic endocrine disease characterized by hyperphagia, or insatiable hunger. Co. develops nevanimibe (ATR-101) with a primary focus on treating patients with congenital adrenal hyperplasia, a monogenic adrenal disease that requires lifelong treatment with exogenous cortisol, often at high doses. Co. also has a neurokinin 3 receptor (NK3R) antagonist (MLE-301), as a potential treatment of vasomotor symptoms, known as hot flashes and night sweats, in menopausal women. We show 10 historical shares outstanding datapoints in our MLND shares outstanding history coverage, used to compute MLND market cap on those dates.
Understanding the changing numbers of shares outstanding, the changing
share price, and the resulting changing MLND market cap history over the course of time is important for investors
interested in comparing MLND's market cap history versus its peers.
Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies,
and then calculating their respective market caps. Comparing the share price of MLND versus a peer is one thing; comparing
MLND market cap versus a peer is a completely different story.
Furthermore, via fluctuation both in per-share price and in the number of shares outstanding (via issuance of new shares over time, the repurchase of existing shares),
the market cap for a company like MLND can fluctuate over the course of history.
With this page we aim to empower investors researching MLND by allowing them to research the MLND market cap history. |
Free MLND Email Alerts:
Video: The Importance of Market Cap
